Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...
Kura Oncology Positioned for Growth with Promising Menin Inhibitor Ziftomenib Amidst Competitor Challenges
Leerink Partners analyst Jonathan Chang has maintained their bullish stance on KURA stock, giving a Buy rating on November 12. Jonathan ...
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their ...
Syndax Pharmaceuticals: Promising Phase 2 Results Justify Buy Rating Amid Market Undervaluation
Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...